Efficacy, Safety, and Tolerability of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate and 17β-Estradiol

Abstract

I.

How to reduce the number of side effects produced by COCs and improve adherence: simple tips for practitioners

“…Однако частота отказов от приема E2/НМГА была выше, чем при приеме E2В/ДНГ, и составила 17,3 против 10,2% соответственно (по срав-нению с ЭЭ/ДРСП -10,4%) [14,16,17].…”

“…Совокупная частота побочных явлений составила 29,4-33,6% (17,6-15,5%) [16,17]. Нежелательные явле-ния, связанные с E2В/ДНГ (с учетом как минимум всех возможных связанных с проводимой терапией нежела-тельных явлений), наблюдались реже -у 19,8% женщин.…”

“…То есть частота отказов от дальней-шего приема составила около 20% [18]. В отношении E2/НМГА, по данным европейских исследований, частота отказов составляет менее 30%, а американских -дости-гает почти 40% [14,17].…”

Changing convention in combination oral contraceptives: estradiol and nomegestrol acetate in a monophasic 24/4 regimen

“…Most recently, the results of a randomised, open-label, comparative multicentre trial performed in several countries, including the USA, of 2281 women randomised in a 3:1 ratio to E2/NOMAC and EE 30 µg/DRSP 3 mg 21/7 were published 29. This study and the clinical outcomes were comparable to those of the Mansour et al 26 study, with E2/NOMAC users characterised by shorter and lighter withdrawal bleeds and a higher frequency of missed withdrawal bleeds than users of EE/DRSP.…”

Choosing a combined oral contraceptive pill

“…However, formulations that combine oestradiol (1.5 mg) in a micronised form with a newer progestogen (nomegestrol) appear to offer good cycle control. 8 Oestradiol has also been combined with a synthetic ester in the form of oestradiol valerate to improve its oral bioavailability and extend its half-life. 9 At the doses prescribed in pills, oestradiol may have a more favourable impact on haemostasis and lipid and carbohydrate metabolism (and therefore on cardiovascular risk) when compared with ethinyloestradiol.…”